D03.9: Melanoma in situ, unspecified
D03.9, melanoma in situ, unspecified, is listed as a covered diagnosis in 4 Medicare billing and coding articles that apply to 33 HCPCS Level II codes, including J9267 (Injection, paclitaxel, 1 mg), J9264 (Injection, paclitaxel protein-bound particles, 1 mg), J8999 (Prescription drug, oral, chemotherapeutic, nos). The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with D03.9 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J9267 | Injection, paclitaxel, 1 mg | Special coverage instructions apply | — | 1 |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Carrier judgment | — | 1 |
| J8999 | Prescription drug, oral, chemotherapeutic, nos | Special coverage instructions apply | — | 1 |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | Special coverage instructions apply | — | 1 |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | Special coverage instructions apply | — | 1 |
| J8530 | Cyclophosphamide; oral, 25 mg | Special coverage instructions apply | — | 1 |
| J8597 | Antiemetic drug, oral, not otherwise specified | Special coverage instructions apply | — | 1 |
| J8610 | Methotrexate; oral, 2.5 mg | Special coverage instructions apply | — | 1 |
| J8498 | Antiemetic drug, rectal/suppository, not otherwise specified | Special coverage instructions apply | — | 1 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Special coverage instructions apply | — | 1 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Special coverage instructions apply | — | 1 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Special coverage instructions apply | — | 1 |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | Special coverage instructions apply | — | 1 |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | Special coverage instructions apply | — | 1 |
| J0890 | Injection, peginesatide, 0.1 mg (for esrd on dialysis) | Carrier judgment | — | 1 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | Special coverage instructions apply | — | 1 |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Special coverage instructions apply | — | 1 |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Carrier judgment | — | 1 |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Special coverage instructions apply | — | 1 |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Special coverage instructions apply | — | 1 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Carrier judgment | — | 1 |
| J1447 | Injection, tbo-filgrastim, 1 microgram | Special coverage instructions apply | — | 1 |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
8 more codes are listed. See every code with payment by region in Caduvo.
Medicare policy articles listing D03.9
- A52450: Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™) (Wellpoint Federal (MAC - Part A, MAC - Part B); 2 Level II codes)
- A52479: Oral Anticancer Drugs - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC); 8 Level II codes). LCD with the same title: L33826
- A56462: Billing and Coding: Erythropoiesis Stimulating Agents (ESA) (CGS Administrators, LLC (MAC - Part A, MAC - Part B); 7 Level II codes). LCD with the same title: L34356
- A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B); 16 Level II codes). LCD with the same title: L37176
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other D03 diagnoses (Melanoma in situ)
- D03.0 — Melanoma in situ of lip
- D03.10 — Melanoma in situ of unspecified eyelid, including canthus
- D03.111 — Melanoma in situ of right upper eyelid, including canthus
- D03.112 — Melanoma in situ of right lower eyelid, including canthus
- D03.121 — Melanoma in situ of left upper eyelid, including canthus
- D03.122 — Melanoma in situ of left lower eyelid, including canthus
- D03.20 — Melanoma in situ of unspecified ear and external auricular canal
- D03.21 — Melanoma in situ of right ear and external auricular canal
- D03.22 — Melanoma in situ of left ear and external auricular canal
- D03.30 — Melanoma in situ of unspecified part of face
- D03.39 — Melanoma in situ of other parts of face
- D03.4 — Melanoma in situ of scalp and neck
- D03.51 — Melanoma in situ of anal skin
- D03.52 — Melanoma in situ of breast (skin) (soft tissue)
- D03.59 — Melanoma in situ of other part of trunk
- D03.60 — Melanoma in situ of unspecified upper limb, including shoulder
- D03.61 — Melanoma in situ of right upper limb, including shoulder
- D03.62 — Melanoma in situ of left upper limb, including shoulder
- D03.70 — Melanoma in situ of unspecified lower limb, including hip
- D03.71 — Melanoma in situ of right lower limb, including hip
- D03.72 — Melanoma in situ of left lower limb, including hip
- D03.8 — Melanoma in situ of other sites
Frequently asked questions
Does Medicare cover D03.9 (Melanoma in situ, unspecified)?
Medicare covers items and services, not diagnoses. 4 Medicare billing and coding articles list D03.9 as a covered diagnosis for 33 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 D03.9?
The Level II codes from the policies most specific to this diagnosis are J9267 (Injection, paclitaxel, 1 mg, 1 article); J9264 (Injection, paclitaxel protein-bound particles, 1 mg, 1 article); J8999 (Prescription drug, oral, chemotherapeutic, nos, 1 article); Q0512 (Pharmacy supply fee for oral anti-cancer, oral anti-emetic…, 1 article); Q0511 (Pharmacy supply fee for oral anti-cancer, oral anti-emetic…, 1 article). Code choice depends on the item supplied; check each code's descriptor.
Which Medicare policy articles list D03.9?
A52450 (Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)); A52479 (Oral Anticancer Drugs - Policy Article); A56462 (Billing and Coding: Erythropoiesis Stimulating Agents (ESA)), and 1 more article.
What is ICD-10-CM code D03.9?
D03.9 is the ICD-10-CM code for melanoma in situ, unspecified, in category D03 (Melanoma in situ), chapter 2: Neoplasms.
Next steps
- Run a reimbursement report for a device billed under J9267
- Watch J9267 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9267
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.